Oaknin, A; Gladieff, L; Martínez-García, J; Villacampa, G; Takekuma, M; De Giorgi, U; Lindemann, K; Woelber, L; Colombo, N; Duska, L; Leary, A; Godoy-Ortiz, A; Nishio, S; Angelergues, A; Rubio, MJ; Fariñas-Madrid, L; Yamaguchi, S; Lorusso, D; Ray-Coquard, I; Manso, L; Joly, F; Alarcón, J; Follana, P; Romero, I; Lebreton, C; Pérez-Fidalgo, JA; Yunokawa, M; Dahlstrand, H; D’Hondt, V; Randall, L – 2024 – 10.1016/S0140-6736(23)02405-4
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial – LANCET
por prodriguez | Ene 1, 2024 | Publicaciones - B-01 | 0 Comentarios